标签归档：hu

青浦沪西智能分配蠕动泵SF100L单通道小流量

发表于由

青浦沪西智能分配蠕动泵SF100L单通道小流量

  • 品牌 青浦沪西|HuXi
  • 型号 SF100L单通道小流量
  • 商品详情

    技术规格

    流量范围:0.008-143ml/min，单通道；

    配置YZ15泵头，适用12#，14#、17#、19#软管；
    转速范围：0.1-150转/分；
    转速分辨率：0.1转/分；精度0.2%；
    调节方式：65565色液晶触摸屏操作；
    采用流量模式，液量分配，时间分配三种模式；
    流量显示，流量控制，流量累计，流量校正功能；
    智能温控功能，最大限度降低蠕动泵噪音；

    • HU药典双频超声清洗器HU10350F/20600F（进口压花不锈钢机壳）

    发表于由

    【简单介绍】

    HU药典双频超声清洗器HU10350F/20600F(进口压花不锈钢机壳)为了配合新版药典在药物样品制备提取时对超声波清洗/提取参数的要求，特开发生产了HU系列超声波药物制备设备。一般建议用户使用单频（主频）超声波；如考虑经济兼顾使用，可选择双频形式的产品。

    金畔生物科技 ：

    【详细说明】

    HU药典双频超声清洗器HU10350F/20600F（进口压花不锈钢机壳）

     

    产品介绍：

        超声波除具有空化作用、热效应和机械作用外，还具有湍动效应、微扰动效应、界面效应和聚能效应等附加效应。通过调节和控制超声波的频率、强度、温度和作用时间，可以强化其中某个效应的影响，减弱或避免其他效应，从而达到提高有效成分提取率的目的。超声波提取参数的选取需根据被提取原料的特性、提取的目的及提取的质量要求综合确定。为了配合新版药典在药物样品制备提取时对超声波清洗/提取参数的要求，特开发生产了HU系列超声波药物制备设备（介绍如下）。一般建议用户使用单频（主频）超声波；如考虑经济兼顾使用，可选择双频形式的产品。

    HU药典双频超声清洗器HU10350F/20600F（进口压花不锈钢机壳）

    产品型号及参数：

    型号中“F”代表“双频”

      


    超生频率选择指南
          研究和实践表明：通常情况下，频率越低，空化效应越显著，粉碎、破裂作用越强。中药在低频超生条件下提取，并不改变药物成分，且一般情况下，频率越低，有效成分提取率越高。但频率越低，空化效应越显著，对中药材组织结构的损伤可能性就越大，可能会产生一些不利的影响。对于某些中药材，超生频率越高，提取率反而越高。这说明频率的影响与中药材的组分、化学形式、生物形式等有关。超生波作用时其效果不仅取决于超声波的强度和频率，而且与被破碎物的结构功能有一定关系。由于提取介质中气泡尺寸不是单一的，而是存在一个分布范围，即有一个带宽，所以超声波频率应有一定范围的变化。请您在综合考虑以上因素的情况下，选择正确的超生频率，以达佳效果。




    Hu7691

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Hu7691 

    Hu7691 是一种具有口服活性的，选择性 Akt 抑制剂，对 Akt1、Akt2 和 Akt3 的 IC50 分别为 4.0 nM、97.5 nM、28 nM。Hu7691 抑制肿瘤生长并降低小鼠的皮肤毒性。

    Hu7691

    Hu7691 Chemical Structure

    CAS No. : 2360523-76-6

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    Hu7691 is an orally active, selective Akt inhibitor with IC50s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 inhibits tumor growth and enables decrease of cutaneous toxicity in mice[1].

    IC50 & Target[1]

    Akt1

    4.0 nM (IC50)

    Akt2

    97.5 nM (IC50)

    Akt3

    28 nM (IC50)

    PKA

    11 nM (IC50)

    PKCη

    629 nM (IC50)

    ROCK1

    354 nM (IC50)

    RSK1

    756 nM (IC50)

    p70S6K

    229 nM (IC50)

    体外研究
    (In Vitro)

    Hu7691 displays low inhibitions against most of the kinases in the four families (AGC, TK, TKL, Lipid/Atypical; PKA, IC50=11 nM; PKCη, IC50=629 nM; ROCK1, IC50=354 nM; RSK1, IC50=756 nM; P70S6K, IC50=229 nM; SGK, IC50=1009 nM)[1].
    Hu7691 (2.25-36 μM; 24 hours) induces effective decrease of the phosphorylation level of Akt (S473)[1].
    B5 (10, 20, 30, 40 μM; for 72 h) exhibits low toxicity against HaCaT cells with an IC50 value of 15.2 μM[1].
    Hu7691 has a significant inhibitory effect on the growth of 18 kinds of human tumor cells (U87-MG, U251, A549, HepG2, HT-29, KHOS, MDA-MB-231, PC3, SKOV3 and so on) derived from different tissues, with the IC50 range of 0.6-27 μM. Hu7691 shows low antiproliferation activities against the HL7702 and HPDE6-C7 normal cells, exhibiting IC50 values of 5.4 and 16.1 μM, respectively[1].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[1]

    Cell Line: HaCaT cells
    Concentration: 2.25, 4.5, 9, 18, 36 μM
    Incubation Time: 24 hours
    Result: Induced effective decrease of the phosphorylation level of Akt (S473).

    体内研究
    (In Vivo)

    Hu7691 (12.5-50 mg/kg/day; i.g.; for 22 days) shows dose-dependent tumor growth inhibition[1].
    Hu7691 (15 mg/kg; oral) has a T1/2 of 8.68 hours, a Cmax of 171.17 ng/mL and an AUC of 2820.64 ng/mL•h in rats[1].
    Hu7691 (2 mg/kg; iv) has a T1/2 of 6.24 hours, a Cmax of 207.52 ng/mL and an AUC of 532.87 ng/mL•h in rats[1].
    Hu7691 (20 mg/kg; oral) has a T1/2 of 16.7 hours, a Cmax of 905.65 ng/mL and an AUC of 36303 ng/mL•h in beagle dog (male, 40 weeks old, 8–10 kg)[1].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Balb/c mice (nu/nu, female, 3-4 weeks old, 20-25 g) with 786-O and KHOS xenograft[1]
    Dosage: 12.5, 25, 50 mg/kg
    Administration: Oral; once daily for 22 days
    Result: Showed dose-dependent tumor growth inhibition.
    Animal Model: SD rats (male, 8 weeks old, 250-300 g)[1]
    Dosage: 15 mg/kg (Pharmacokinetic Analysis)
    Administration: Oral
    Result: Had a T1/2 of 8.68 hours, a Cmax of 171.17 ng/mL and an AUC of 2820.64 ng/mL•h.

    分子量

    450.88

    Formula

    C22H22ClF3N4O
    CAS 号

    2360523-76-6
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Jinxin Che, et al. Discovery of N-((3 S,4 S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1 H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity. J Med Chem. 2021 Aug 26;64(16):12163-12180.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    Hu7691 free base

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Hu7691 free base 

    Hu7691 free base 是一种具有口服活性的，选择性 Akt 抑制剂，对 Akt1、Akt2 和 Akt3 的 IC50 分别为 4.0 nM、97.5 nM、28 nM。Hu7691 free base 抑制肿瘤生长并降低小鼠的皮肤毒性。

    Hu7691 free base

    Hu7691 free base Chemical Structure

    CAS No. : 2241232-43-7

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    Hu7691 free base is an orally active, selective Akt inhibitor with IC50s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 free base inhibits tumor growth and enables decrease of cutaneous toxicity in mice[1].

    IC50 & Target[1]

    Akt1

    4.0 nM (IC50)

    Akt2

    97.5 nM (IC50)

    Akt3

    28 nM (IC50)

    PKA

    11 nM (IC50)

    PKCη

    629 nM (IC50)

    ROCK1

    354 nM (IC50)

    RSK1

    756 nM (IC50)

    p70S6K

    229 nM (IC50)

    体外研究
    (In Vitro)

    Hu7691 free base displays low inhibitions against most of the kinases in the four families (AGC, TK, TKL, Lipid/Atypical; PKA, IC50=11 nM; PKCη, IC50=629 nM; ROCK1, IC50=354 nM; RSK1, IC50=756 nM; P70S6K, IC50=229 nM; SGK, IC50=1009 nM)[1].
    Hu7691 free base (2.25-36 μM; 24 hours) induces effective decrease of the phosphorylation level of Akt (S473)[1].
    Hu7691 free base (10, 20, 30, 40 μM; for 72 h) exhibits low toxicity against HaCaT cells with an IC50 value of 15.2 μM[1].
    Hu7691 free base has a significant inhibitory effect on the growth of 18 kinds of human tumor cells (U87-MG, U251, A549, HepG2, HT-29, KHOS, MDA-MB-231, PC3, SKOV3 and so on) derived from different tissues, with the IC50 range of 0.6-27 μM. Hu7691 free base shows low antiproliferation activities against the HL7702 and HPDE6-C7 normal cells, exhibiting IC50 values of 5.4 and 16.1 μM, respectively[1].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[1]

    Cell Line: HaCaT cells
    Concentration: 2.25, 4.5, 9, 18, 36 μM
    Incubation Time: 24 hours
    Result: Induced effective decrease of the phosphorylation level of Akt (S473).

    体内研究
    (In Vivo)

    Hu7691 free base (12.5-50 mg/kg/day; i.g.; for 22 days) shows dose-dependent tumor growth inhibition[1].
    Hu7691 free base (15 mg/kg; oral) has a T1/2 of 8.68 hours, a Cmax of 171.17 ng/mL and an AUC of 2820.64 ng/mL•h in rats[1].
    Hu7691 free base (2 mg/kg; iv) has a T1/2 of 6.24 hours, a Cmax of 207.52 ng/mL and an AUC of 532.87 ng/mL•h in rats[1].
    Hu7691 free base (20 mg/kg; oral) has a T1/2 of 16.7 hours, a Cmax of 905.65 ng/mL and an AUC of 36303 ng/mL•h in beagle dog (male, 40 weeks old, 8–10 kg)[1].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Balb/c mice (nu/nu, female, 3-4 weeks old, 20-25 g) with 786-O and KHOS xenograft[1]
    Dosage: 12.5, 25, 50 mg/kg
    Administration: Oral; once daily for 22 days
    Result: Showed dose-dependent tumor growth inhibition.
    Animal Model: SD rats (male, 8 weeks old, 250-300 g)[1]
    Dosage: 15 mg/kg (Pharmacokinetic Analysis)
    Administration: Oral
    Result: Had a T1/2 of 8.68 hours, a Cmax of 171.17 ng/mL and an AUC of 2820.64 ng/mL•h.

    分子量

    414.42

    Formula

    C22H21F3N4O
    CAS 号

    2241232-43-7
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Jinxin Che, et al. Discovery of N-((3 S,4 S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1 H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity. J Med Chem. 2021 Aug 26;64(16):12163-12180.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务